The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted ...
A major investigation into the real-world effects of the JAK1 inhibitor abrocitinib, in a study called the "Abrocitinib CHinese rEgistry on AD" (AHEAD), made its international debut at the 83rd Annual ...
Asian News International on MSN2h
From Classroom to Clinics: How TAU Prepares You for a Successful Medical CareerEmbarking on a medical career is an exciting yet demanding journey. Medical education involves mastering complex scientific ...
GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This 'first ...
Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...
Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 - - Completed upsized IPO with ...
Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback